Evidence Table D-49. Continuous cardiac outcomes for studies comparing interventions to treat delirium

| Author, year | Study design | Population | Intervention group, n | Control group, n | Route of administration | Outcome definition | MMSE, intervention group | MMSE, control group | Mean between-group difference (95% CI) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| First-generation antipsychotic vs. placebo |  |  |  |  |  |  |  |  |  |
| Naksuk, 2017[51](#_ENREF_51) | Case control analyzed as cohort with comparison group | Patients admitted to the coronary care unit | Haloperidol (Median dose: 5.0 Dose range: 1.0 to 57.5mg), 124 | Not Reported, 681 | Not reported | Prolongation in the QTc interval milliseconds | Baseline: Mean 448 (SD 56)Final: Mean 471 (SD 52) | Baseline: Mean 459 (SD 60)Final: Mean (SD ) |   |
| Naksuk, 2017[51](#_ENREF_51) | Case control analyzed as cohort with comparison group | Patients admitted to the coronary care unit | Haloperidol (Median dose: 5.0 Dose range: 1.0 to 57.5mg), 124 | Not Reported, 681 | Not reported | Prolongation in the QTc interval milliseconds | Baseline: Mean 448 (SD 56)Final: Mean 426 (SD 64) | Baseline: Mean 459 (SD 60)Final: Mean (SD ) |   |
| Naksuk, 2017[51](#_ENREF_51) | Case control analyzed as cohort with comparison group | Patients admitted to the coronary care unit | Haloperidol (Median dose: 5.0 Dose range: 1.0 to 57.5mg), 124 | Not Reported, 681 | Not reported | Prolongation in the QTc interval milliseconds | Baseline: Mean 448 (SD 56)Final: Mean 442 (SD 34) | Baseline: Mean 459 (SD 60)Final: Mean 458 (SD 44) | -5.00 (95% CI: -194.06 to 184.06) |
| Naksuk, 2017[51](#_ENREF_51) | Case control analyzed as cohort with comparison group | Patients admitted to the coronary care unit | Haloperidol (Median dose: 5.0 Dose range: 1.0 to 57.5mg), 124 | Not Reported, 681 | Not reported | Prolongation in the QTc interval milliseconds | Baseline: Mean 448 (SD 56)Final: Mean 458 (SD 57) | Baseline: Mean 459 (SD 60)Final: Mean (SD ) |   |
| Naksuk, 2017[51](#_ENREF_51) | Case control analyzed as cohort with comparison group | Patients admitted to the coronary care unit | Haloperidol (Median dose: 5.0 Dose range: 1.0 to 57.5mg), 124 | Not Reported, 681 | Not reported | Prolongation in the QTc interval milliseconds | Baseline: Mean 448 (SD 56)Final: Mean 454 (SD 49) | Baseline: Mean 459 (SD 60)Final: Mean (SD ) |   |

| Author, year | Study design | Population | Intervention group, n | Control group, n | Route of administration | Outcome definition | MMSE, intervention group | MMSE, control group | Mean between-group difference (95% CI) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Second-generation antipsychotic vs. placebo |  |  |  |  |  |  |  |  |  |
| Naksuk, 2017[51](#_ENREF_51) | Case control analyzed as cohort with comparison group | Patients admitted to the coronary care unit | Quetiapine (Median dose: 25.0 Dose range: 4.2 to 150.0mg), 59 | Not Reported, 681 | Not reported | Prolongation in the QTc interval milliseconds | Baseline: Mean 470 (SD 66)Final: Mean 455 (SD 53) | Baseline: Mean 459 (SD 60)Final: Mean (SD ) |   |
| Naksuk, 2017[51](#_ENREF_51) | Case control analyzed as cohort with comparison group | Patients admitted to the coronary care unit | Quetiapine (Median dose: 25.0 Dose range: 4.2 to 150.0mg), 59 | Not Reported, 681 | Not reported | Prolongation in the QTc interval milliseconds | Baseline: Mean 470 (SD 66)Final: Mean 451 (SD 51) | Baseline: Mean 459 (SD 60)Final: Mean (SD ) |   |
| Naksuk, 2017[51](#_ENREF_51) | Case control analyzed as cohort with comparison group | Patients admitted to the coronary care unit | Quetiapine (Median dose: 25.0 Dose range: 4.2 to 150.0mg), 59 | Not Reported, 681 | Not reported | Prolongation in the QTc interval milliseconds | Baseline: Mean 470 (SD 66)Final: Mean 454 (SD 51) | Baseline: Mean 459 (SD 60)Final: Mean 458 (SD 44) | -15.00 (95% CI: -201.67 to 171.67) |
| Naksuk, 2017[51](#_ENREF_51) | Case control analyzed as cohort with comparison group | Patients admitted to the coronary care unit | Quetiapine (Median dose: 25.0 Dose range: 4.2 to 150.0mg), 59 | Not Reported, 681 | Not reported | Prolongation in the QTc interval milliseconds | Baseline: Mean 470 (SD 66)Final: Mean 467 (SD 68) | Baseline: Mean 459 (SD 60)Final: Mean (SD ) |   |
| Naksuk, 2017[51](#_ENREF_51) | Case control analyzed as cohort with comparison group | Patients admitted to the coronary care unit | Quetiapine (Median dose: 25.0 Dose range: 4.2 to 150.0mg), 59 | Not Reported, 681 | Not reported | Prolongation in the QTc interval milliseconds | Baseline: Mean 470 (SD 66)Final: 457 ( 41) | Baseline: Mean 459 (SD 60)Final: ( ) |   |

| Author, year | Study design | Population | Intervention group, n | Control group, n | Route of administration | Outcome definition | MMSE, intervention group | MMSE, control group | Mean between-group difference (95% CI) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| First-generation antipsychotic vs. second-generation antipsychotic |  |  |  |  |  |  |  |  |  |
| Naksuk, 2017[51](#_ENREF_51) | Case control analyzed as cohort with comparison group | Patients admitted to the coronary care unit | Quetiapine (Median dose: 25.0 Dose range: 4.2 to 150.0mg), 59 | Haloperidol (Median dose: 5.0 Dose range: 1.0 to 57.5mg), 124 | Median dose: 25.0 Dose range: 4.2 to 150.0mg | 24 hours after last dose | Baseline: Mean 470 (SD 66)Final: Mean 455 (SD 53) | Baseline: Mean 448 (SD 56)Final: Mean 471 (SD 52) | -38.00 (95% CI: -268.46 to 192.46) |
| Naksuk, 2017[51](#_ENREF_51) | Case control analyzed as cohort with comparison group | Patients admitted to the coronary care unit | Quetiapine (Median dose: 25.0 Dose range: 4.2 to 150.0mg), 59 | Haloperidol (Median dose: 5.0 Dose range: 1.0 to 57.5mg), 124 | Median dose: 25.0 Dose range: 4.2 to 150.0mg | 48 hours after last dose | Baseline: Mean 470 (SD 66)Final: Mean 451 (SD 51) | Baseline: Mean 448 (SD 56)Final: Mean 426 (SD 64) | 3.00 (95% CI: -242.80 to 248.80) |
| Naksuk, 2017[51](#_ENREF_51) | Case control analyzed as cohort with comparison group | Patients admitted to the coronary care unit | Quetiapine (Median dose: 25.0 Dose range: 4.2 to 150.0mg), 59 | Haloperidol (Median dose: 5.0 Dose range: 1.0 to 57.5mg), 124 | Median dose: 25.0 Dose range: 4.2 to 150.0mg | During admission (mean QTc intervals during CCU admission, excluding baseline) | Baseline: Mean 470 (SD 66)Final: Mean 454 (SD 51) | Baseline: Mean 448 (SD 56)Final: Mean 442 (SD 34) | -10.00 (95% CI: -216.57 to 196.57) |
| Naksuk, 2017[51](#_ENREF_51) | Case control analyzed as cohort with comparison group | Patients admitted to the coronary care unit | Quetiapine (Median dose: 25.0 Dose range: 4.2 to 150.0mg), 59 | Haloperidol (Median dose: 5.0 Dose range: 1.0 to 57.5mg), 124 | Median dose: 25.0 Dose range: 4.2 to 150.0mg | During therapy within 6 hours after each dose | Baseline: Mean 470 (SD 66)Final: Mean 467 (SD 68) | Baseline: Mean 448 (SD 56)Final: Mean 458 (SD 57) | -13.00 (95% CI: -260.81 to 234.81) |
| Naksuk, 2017[51](#_ENREF_51) | Case control analyzed as cohort with comparison group | Patients admitted to the coronary care unit | Quetiapine (Median dose: 25.0 Dose range: 4.2 to 150.0mg), 59 | Haloperidol (Median dose: 5.0 Dose range: 1.0 to 57.5mg), 124 | Median dose: 25.0 Dose range: 4.2 to 150.0mg | During therapy within 6 hours after third dose | Baseline: Mean 470 (SD 66)Final: Mean 457 (SD 41) | Baseline: Mean 448 (SD 56)Final: Mean 454 (SD 49) | -19.00 (95% CI: -237.62 to 199.62) |

CCU=coronary care unit; CI=confidence interval; mg=milligram; QTc=corrected QT interval